Vascular Solutions Inc. (VASC) PT Raised to $49.00
Vascular Solutions Inc. (NASDAQ:VASC) had its target price lifted by equities research analysts at Piper Jaffray Cos. from $45.00 to $49.00 in a research note issued to investors on Tuesday. The brokerage presently has an “overweight” rating on the medical device company’s stock. Piper Jaffray Cos.’s price target indicates a potential upside of 2.96% from the stock’s current price.
A number of other analysts also recently weighed in on VASC. Zacks Investment Research raised shares of Vascular Solutions from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research note on Thursday, April 28th. Sidoti cut shares of Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 price target for the company. in a research note on Tuesday, July 12th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $49.50.
Shares of Vascular Solutions (NASDAQ:VASC) traded down 1.35% on Tuesday, reaching $47.59. The company had a trading volume of 90,344 shares. The company’s 50-day moving average is $48.49 and its 200-day moving average is $41.58. The company has a market capitalization of $832.40 million, a PE ratio of 88.13 and a beta of 0.54. Vascular Solutions has a one year low of $24.34 and a one year high of $50.72.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/vascular-solutions-inc-vasc-pt-raised-to-49-00.html
Vascular Solutions (NASDAQ:VASC) last announced its quarterly earnings data on Monday, July 25th. The medical device company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.03. The firm had revenue of $41.20 million for the quarter, compared to the consensus estimate of $41.40 million. Vascular Solutions had a net margin of 6.22% and a return on equity of 16.32%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.29 EPS. Equities research analysts predict that Vascular Solutions will post $1.24 earnings per share for the current year.
In other news, VP William Rutstein sold 10,011 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $46.26, for a total value of $463,108.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Howard Root sold 40,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $45.11, for a total transaction of $1,804,400.00. Following the completion of the sale, the chief executive officer now directly owns 347,840 shares in the company, valued at $15,691,062.40. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in VASC. JPMorgan Chase & Co. bought a new position in Vascular Solutions during the first quarter valued at about $122,000. Mason Street Advisors LLC bought a new position in Vascular Solutions during the second quarter valued at about $141,000. Envestnet Asset Management Inc. increased its position in Vascular Solutions by 11.6% in the first quarter. Envestnet Asset Management Inc. now owns 6,036 shares of the medical device company’s stock valued at $196,000 after buying an additional 628 shares during the last quarter. Bank of Montreal Can bought a new position in Vascular Solutions during the second quarter valued at about $202,000. Finally, First Mercantile Trust Co. increased its position in Vascular Solutions by 129.4% in the third quarter. First Mercantile Trust Co. now owns 4,242 shares of the medical device company’s stock valued at $205,000 after buying an additional 2,393 shares during the last quarter. 82.08% of the stock is currently owned by hedge funds and other institutional investors.
About Vascular Solutions
Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.
Receive News & Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.